Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men.
Fan
Y M
YM
Laaksonen
R
R
Janatuinen
T
T
Vesalainen
R
R
Nuutila
P
P
Knuuti
J
J
Lehtimäki
T
T
D000328:Adult; D000704:Analysis of Variance; D001783:Blood Flow Velocity / Q000187:drug effects; D003324:Coronary Artery Disease / Q000235:genetics; D003326:Coronary Circulation / Q000187:drug effects* / Q000235:genetics; D004562:Electrocardiography; D005500:Follow-Up Studies; D005838:Genotype; D006321:Heart / Q000187:drug effects*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008055:Lipids / Q000097:blood*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*; D017035:Pravastatin / Q000494:pharmacology*
D047908:Intracellular Signaling Peptides and Proteins; D008055:Lipids; D008565:Membrane Proteins; C102196:SREBP cleavage-activating protein; D017035:Pravastatin